IRIS
VIGNA, ERNESTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.505
NA - Nord America 1.403
EU - Europa 800
SA - Sud America 752
AF - Africa 114
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
AN - Antartide 1
Totale 5.582
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.295
SG - Singapore 954
BR - Brasile 559
CN - Cina 480
VN - Vietnam 464
IT - Italia 310
HK - Hong Kong 192
FR - Francia 103
DE - Germania 92
AR - Argentina 64
KR - Corea 64
FI - Finlandia 57
MX - Messico 50
BD - Bangladesh 45
IN - India 44
GB - Regno Unito 42
IQ - Iraq 42
CA - Canada 32
ZA - Sudafrica 32
EC - Ecuador 31
RU - Federazione Russa 30
PK - Pakistan 29
UA - Ucraina 29
NL - Olanda 28
CO - Colombia 27
ID - Indonesia 26
AT - Austria 24
UZ - Uzbekistan 20
TR - Turchia 19
PH - Filippine 17
CL - Cile 15
VE - Venezuela 15
ES - Italia 14
PY - Paraguay 14
DZ - Algeria 13
MA - Marocco 13
PL - Polonia 13
SA - Arabia Saudita 13
JP - Giappone 12
KE - Kenya 11
UY - Uruguay 11
TN - Tunisia 10
ET - Etiopia 9
JO - Giordania 9
AE - Emirati Arabi Uniti 8
EG - Egitto 8
IL - Israele 8
PE - Perù 8
BO - Bolivia 7
KG - Kirghizistan 7
LB - Libano 7
PA - Panama 7
MY - Malesia 6
AL - Albania 5
AZ - Azerbaigian 5
BA - Bosnia-Erzegovina 5
CR - Costa Rica 5
CZ - Repubblica Ceca 5
NP - Nepal 5
OM - Oman 5
SE - Svezia 5
BG - Bulgaria 4
DO - Repubblica Dominicana 4
PS - Palestinian Territory 4
RO - Romania 4
SN - Senegal 4
AU - Australia 3
CH - Svizzera 3
KZ - Kazakistan 3
NG - Nigeria 3
QA - Qatar 3
RS - Serbia 3
SC - Seychelles 3
SK - Slovacchia (Repubblica Slovacca) 3
BE - Belgio 2
BN - Brunei Darussalam 2
BY - Bielorussia 2
DK - Danimarca 2
GT - Guatemala 2
KH - Cambogia 2
KW - Kuwait 2
LT - Lituania 2
LY - Libia 2
MK - Macedonia 2
NI - Nicaragua 2
NO - Norvegia 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
AM - Armenia 1
AQ - Antartide 1
BS - Bahamas 1
BW - Botswana 1
CG - Congo 1
CI - Costa d'Avorio 1
CW - ???statistics.table.value.countryCode.CW??? 1
GA - Gabon 1
GE - Georgia 1
GR - Grecia 1
GY - Guiana 1
Totale 5.564
Salva come PNG Salva come JPEG
Città #
Singapore 424
San Jose 233
Dallas 226
Hong Kong 190
Ashburn 163
Ho Chi Minh City 163
Florence 136
Boardman 135
Hefei 103
Beijing 100
Hanoi 97
Seoul 63
Lauterbourg 62
São Paulo 56
Shanghai 47
Munich 41
Helsinki 40
Los Angeles 37
Rio de Janeiro 24
Da Nang 23
Haiphong 22
Sesto Fiorentino 22
Milan 21
New York 20
Noto 20
Council Bluffs 18
Guangzhou 18
Santa Clara 18
Baghdad 17
Tashkent 17
Montreal 16
Quito 16
Brasília 13
Brooklyn 13
The Dalles 13
Vienna 13
Mexico City 12
Washington 12
Amsterdam 11
Johannesburg 11
Orem 11
Rome 11
Tokyo 11
Catania 10
Guayaquil 10
Hillsboro 10
Lahore 10
Nairobi 10
Addis Ababa 9
Amman 9
Biên Hòa 9
Frankfurt am Main 9
Ninh Bình 9
Thái Nguyên 9
Turku 9
Wuhan 9
Belo Horizonte 8
Chennai 8
Dhaka 8
Karachi 8
Lappeenranta 8
London 8
Medellín 8
Montevideo 8
Warsaw 8
Campinas 7
Caracas 7
Erbil 7
Fortaleza 7
Kyiv 7
Naaldwijk 7
Naples 7
Nuremberg 7
Ogden 7
Phoenix 7
Ribeirão Preto 7
San Francisco 7
Atlanta 6
Bishkek 6
Bogotá 6
Can Tho 6
Cape Town 6
Charlotte 6
Chicago 6
Curitiba 6
Portland 6
Santiago 6
Boston 5
Bragança Paulista 5
Duhok 5
Feira de Santana 5
Hangzhou 5
Hải Dương 5
Manaus 5
Recife 5
Riyadh 5
Santo André 5
Thái Bình 5
Uberlândia 5
Americana 4
Totale 3.121
Salva come PNG Salva come JPEG
Nome #
Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options? 160
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 123
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 120
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 113
Efficacy of eculizumab in severe ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) refractory to standard therapies 112
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study 108
Momelotinib in myelofibrosis 108
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 107
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma 105
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol 104
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 104
Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia Successfully Treated with Rituximab-Venetoclax: A Case Report 104
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 102
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 99
TP53‐Mutated Acute Myeloid Leukemia: Unanswered Questions 99
Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data 97
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials 97
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study 96
Vaccination in Multiple Myeloma: Challenges and Strategies 96
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 96
Belantamab mafodotin in multiple myeloma 96
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 93
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 90
Iron chelation therapy 90
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 89
Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging Perspectives 86
Elotuzumab in multiple myeloma 85
Acalabrutinib in chronic lymphocytic leukemia 84
Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities 83
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort 80
Cerebral pheohyphomycosis due to curvularia species 79
Ivosidenib in acute myeloid leukemia 79
Selinexor in multiple myeloma 79
Teclistamab-cqyv in multiple myeloma 79
Rilzabrutinib for the Treatment of Immune Thrombocytopenia 78
Myelodysplastic syndromes with ring sideroblasts 76
Frailty predicts treatment-related toxicity and discontinuation in older adults with chronic lymphocytic leukemia treated with BTK and BCL-2 inhibitors: Findings from a prospective single-center cohort study 76
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials 76
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature 76
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients 75
The role of corticosteroids in the current treatment paradigm for myelofibrosis 72
Avatrombopag for the Treatment of Immune Thrombocytopenia 71
Comparison of two scores in predicting pulmonary embolism-related adverse events in intermediate-high-risk patients: a systematic review and meta-analysis 70
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients 69
Zanubrutinib for the treatment of chronic lymphocytic leukemia 69
Advances and Challenges in Quizartinib‐Based FLT3 Inhibition for Acute Myeloid Leukemia: Mechanisms of Resistance and Prospective Combination Therapies 69
Eltrombopag treatment for severe immune thrombocytopenia during pregnancy: a case report 68
Maintenance therapy after ASCT in newly diagnosed multiple myeloma patients: single agent versus combination drugs 67
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study 66
Glasdegib for the treatment of acute myeloid leukemia 66
Multisystem Inflammatory Syndrome after Ad26.COV2.S vaccination 65
A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients 64
Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions 63
Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura 58
Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications 57
Mosunetuzumab for the treatment of follicular lymphoma 57
Treatment-Free Remission in Chronic Myeloid Leukemia: Revisiting the "W" Questions 57
Potential of BGB-1417, a BCL2 inhibitor, in hematological malignancies 54
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens 54
Performance of the Bova score in predicting short-term all-cause mortality in patients with pulmonary embolism and normal blood pressure. A systematic review and meta-analysis 48
Venetoclax in acute myeloid leukemia 48
Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents 47
Isatuximab in multiple myeloma 46
The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia 44
Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies 43
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real‐World Study 34
Herpes Zoster in Hematological Disorders: Pathogenesis, Risk Stratification, and Emerging Strategies for Prevention and Immunization 34
Real‐World Evaluation of Oral Decitabine/Cedazuridine in Elderly Patients With Acute Myeloid Leukemia 30
Extracellular vesicles in multiple myeloma-bone marrow niche crosstalk: from cellular dialogue to clinical perspectives 29
Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia 26
Clonal haematopoiesis in chronic lymphocytic leukaemia: Biology, inflammaging and clinical implications in the era of targeted therapy 23
Hypomethylating agents alone or in combination with venetoclax in very elderly acute myeloid leukemia patients: less treatment, better care? 23
Chemotherapy‐Sparing Strategies in Follicular Lymphoma: Emerging Targeted and Immune‐Based Approaches 20
Beyond PD‐1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next‐Generation Immune Strategies 20
Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies 18
Management of Primary Refractory Diffuse Large B‐Cell Lymphoma in Patients Unsuitable for CAR T‐Cell Therapy 15
Targeting the Menin– KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical Translation 14
Comparative efficacy of different therapeutic approaches in treatment naïve FLT3-mutated AML eligible for intensive chemotherapy: a Bayesian network meta-analysis of randomized trials 14
Relapse Despite MRD Negativity in Multiple Myeloma: Toward Integrated Risk Prediction 13
Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort 13
Reshaping multiple myeloma treatment: recent breakthroughs 13
Frontline Therapy in Diffuse Large B‐Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions 12
Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM 10
Ph‐Negative Acute Lymphoblastic Leukemia in the Older Adults: Biology, Therapeutic Strategies and Unmet Needs 10
Exploiting ALK inhibition in anaplastic large cell lymphoma: Biological rationale and therapeutic integration 9
Therapeutic Strategies for Relapsed or Refractory B‐Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies 8
Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives 7
Totale 5.686
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.662
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.662
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211 0 0 0 0 0 0 0 0 0 1 0 0
2021/20228 0 2 0 0 2 0 0 1 0 0 1 2
2022/202375 2 0 0 2 1 1 32 2 4 5 20 6
2023/2024530 10 17 105 84 49 64 24 17 17 8 19 116
2024/20251.200 45 99 33 62 59 45 24 61 178 124 123 347
2025/20263.865 424 237 407 305 694 326 484 226 366 396 0 0
Totale 5.686